

USFDA nod to Zydus for anti-cholesterol drug

27 April 2017 | News

Zydus Cadila has received approval to market an anti-cholesterol drug, Cholestyramine, in the American market.



Drug firm Zydus Cadila has received approval from the US health regulator to market an anti-cholesterol drug, Cholestyramine, in the American market.

The US is the world's largest drug market and approvals to sell generic medicines there provide companies opportunities to increase their revenue.

The drug Cholestyramine is indicated as an adjunctive therapy to the diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet.

The product would be manufactured at the company's facility at Baddi in Himachal Pradesh.

The group has now more than 110 approvals and has so far filled over 300 ANDAs since the commencement of the filling process in financial year 2003-2004.